Methods and compositions for therapeutic treatment of viral or virally-induced infections and conditions, and anti-viral compositions and their production

Abstract

Methods and compositions for treating a viral infection, where the cells from the host to be treated are extracted from the host and modified with viral DNA, and then replaced back to the host to generate an immune response. The composition may be produced using fat cells that are mechanically or chemically transformed to a nanofat, and co-incubation of the nanofat with the adenovirus. The double-stranded DNA of the adenovirus codes for a specific antibody to be produced, and the transfer of genetic material from the virus to the nanofat stem cells takes place outside of the host where the host immune system cannot destroy it. The co-incubated cells are then administered to the host by introduction into the nasal passages or directive cavity, or through injection or other vehicle. The compositions provide an effective rapid response to an invasive pathogen, such as an adenovirus or bacteria, through passive immunity.

What is claimed is: 
     
         1 . A method of delivering passive immunity against a pathogen to a mammalian host, comprising:
 a) extracting fat tissue of the mammalian host to be immunized;   b) homogenizing the extracted fat tissue to extract the stem cell fraction (SVF) that contains the Adipose tissue-derived stem cells (ADSC);   c) separating the fat fractions to obtain the nanofat containing the Adipose tissue-derived stem cells (ADSC);   d) co-incubating the nanofat with the pathogen or pathogenic antigen to form an immunogenic composition; and   e) administering to said mammalian host the immunogenic composition.   
     
     
         2 . The method of  claim 1 , wherein said nanofat comprises the stromal vascular fraction (SVF) of the fat tissue extracted from the host and contains Adipose tissue-derived stem cells (ADSC). 
     
     
         3 . The method of  claim 2 , including culturing the extracted stem cells prior to co-incubation with said gene for the antibody. 
     
     
         4 . The method of  claim 2 , wherein the adenovirus is co-incubated with the ADSC (extracted stem cells) directly. 
     
     
         5 . The method of  claim 1 , wherein the gene coding for the antibody to said pathogen is an adenovirus and wherein said adenovirus codes for the gene of the antibody. 
     
     
         6 . The method of  claim 5 , wherein administering the immunogenic composition to said host includes spraying the immunologic composition into the mucosa of the digestive and/or respiratory tract of the host, or injecting the immunologic composition into the host via injecting into the skin, subcutaneous tissue, muscle or into a blood vessel. 
     
     
         7 . The method of  claim 5 , wherein co-incubation is carried out by transfection of said nanofat with said adenovirus. 
     
     
         8 . The method of  claim 7 , wherein said adenovirus is an antibody specific to the corona virus (COVID-19). 
     
     
         9 . The method of  claim 8 , wherein said coronavirus is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the coronavirus disease (COVID-19). 
     
     
         10 . The method of  claim 8 , including repeating step e) at a plurality of spaced apart time intervals. 
     
     
         11 . An immunologic composition for treating a viral infection by a virus in a host comprising:
 a modified host-generated stem cells transformed from nanofat having the viral DNA of the antibody directed against the viral infection to be treated, the modified host-generated stem cells being transformed to produce antibodies to the virus.   
     
     
         12 . The composition of  claim 11 , wherein said modified host-generated stem cells comprise modified host-generated Adipose tissue-derived stem cells (ADSC) of the stromal vascular fraction (SVF) of fat cells from the host. 
     
     
         13 . The immunologic composition of  claim 11 , wherein said viral DNA is an adenovirus DNA. 
     
     
         14 . The immunologic composition of  claim 11 , wherein said adenovirus DNA is a gene that codes for the antibody against the adenovirus which is endangering the host. 
     
     
         15 . The immunologic composition of  claim 14 , wherein said adenovirus DNA is a gene that codes for the antibody against the coronavirus which is endangering the host. 
     
     
         16 . The immunologic composition of  claim 15 , wherein said coronavirus is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the coronavirus disease (COVID-19). 
     
     
         17 . A method of producing an immunologic composition for treating a viral infection in a mammalian host comprising:
 a) extracting fat tissue of the mammalian host to be immunized;   b) homogenizing the extracted fat tissue to extract the stem cell fraction (SVF) that contains the Adipose tissue-derived stem cells (ADSC);   c) separating the extracted fat tissue in step b) to obtain the nanofat fraction containing the Adipose tissue-derived stem cells (ADSC) by passing the fat tissue through a 500 micro mesh screen;   d) co-incubating the nanofat fraction with the pathogen or pathogenic antigen to form an immunogenic composition that comprises antibodies against the virus;   e) wherein said nanofat comprises the stromal vascular fraction (SVF) of the fat tissue extracted from the host and contains Adipose tissue-derived stem cells (ADSC); and   f) wherein said viral infection to be treated is a virus that is attacking the host, or to which the host is susceptible.   
     
     
         18 . The method of  claim 17 , wherein said viral infection to be treated is coronavirus (COVID19), and wherein said pathogen is coronavirus (COVID19) or pathogenic antigen is coronavirus (COVID19) antigen. 
     
     
         19 . The method of  claim 17 , including an optional step of culturing the nanofat fraction passing through the 500 mesh screen in step c) that contains the Adipose tissue-derived stem cells (ADSC) in a cell-sustaining culture medium; and co-incubating the cultured nanofat fraction with the pathogen or pathogenic antigen to form an immunogenic composition that comprises antibodies to the virus. 
     
     
         20 . The method of  claim 1 , wherein said mammalian host that receives the immunologic composition is asymptomatic or has no known prior exposure to the pathogen. 
     
     
         21 . The method of  claim 1 , wherein said mammalian host that receives the immunologic composition is symptomatic or is confirmed to have an infection from the pathogen. 
     
     
         22 . The method of  claim 1 , wherein homogenizing and/or separating the fat fractions to obtain the nanofat containing the Adipose tissue-derived stem cells (ADSC) comprises mechanical manipulation. 
     
     
         23 . The method of  claim 1 , wherein homogenizing and/or separating the fat fractions to obtain the nanofat containing the Adipose tissue-derived stem cells (ADSC) comprises a chemical treatment.